For the quarter ending 2025-09-30, PVLA had -$6,866K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,345 | -17,656 |
| Non-cash interest expense - royalty agreement | 1,510 | 2,569 |
| Non-cash interest expense - convertible note | 0 | - |
| Change in fair value of derivative liabilities - royalty agreement | 82 | 193 |
| Change in fair value of derivative liabilities - contingent value right agreement | 238 | - |
| Change in fair value of convertible notes payable | 0 | - |
| Stock-based compensation | 1,790 | 2,527 |
| Costs to issue convertible notes | 0 | 0 |
| Accounts receivable | 0 | -358 |
| Prepaid expenses and other current assets | -182 | -960 |
| Accounts payable | -1,136 | 1,240 |
| Accrued expenses and other current liabilities | 801 | -2,393 |
| Net cash used in operating activities | -7,878 | -12,202 |
| Payment of transaction costs in connection with reverse merger | 0 | 1,269 |
| Proceeds from issuance of convertible notes payable | 0 | 0 |
| Payment of transaction costs to issue convertible notes | 0 | 0 |
| Proceeds from exercise of stock options | 242 | 416 |
| Net cash (used in) provided by financing activities | 242 | -853 |
| Effect of exchange rate change on cash and cash equivalents | 770 | -114 |
| Net (decrease) increase in cash and cash equivalents | -6,866 | -13,169 |
| Cash and cash equivalents at beginning of period | 83,602 | - |
| Cash and cash equivalents at end of period | 63,567 | - |
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)